+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level



Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level



Zhonghua Xinxueguanbing Zazhi 32(2): 109-113, February 19



Objective To observe the influence of simvastatin on serum matrix metalloproteinases-1 (MMP-1), MMP-9, tissue inhibitor of metalloproteinases-1 (TIMP-1), MMP-9/TIMP-1, and high sensitive C-reactive protein ( hs-CRP) levels in patients of acute coronary syndrome (ACS) with serum normochulestemia level (NC group) and hypercholesterolemia level (HC group). Methods Sixty-two NC and Sixty-nine HC patients of ACS were stratified by randomized, double-blind, contrastive assigned to simvastal in group (20 mg/d of simvastatin for 8 weeks. NC group, n = 33. HC group, n = 36) or to the control group (no lipid-lowering drugs. NC group, n = 32. HC group, n = 36). The serum levels of MMP-1, N1MP-9, TIMP-1, MMP-9/TIMP-1, hs-CRP before and after treatment were detected. Results (1) The patients with ACS both NC group and HC group had higher levels of serum MMP-1, MMP-9, TIMP-1, MMP-9/IMP-1 and hs-CRP compared with those of healthy group (P < 0.001, P < 0. 05, P < 0.01. n = 60) and had no correlation to levels of serum lipids. (2) After treatment of simvastatin, the levels of serum MMP-1, MMP-9, MMP-9/TIMP-1, and hs-CRP in both two groups of simvastatin treatment significantly decreased (P < 0.001, P < 0.01), serum TIMP-1 had no change. The levels of serum TC, TG, LDL-C in HC group of simvastatin treatment significantly reduced (P < 0. 001) and those of serum TC, LDL-C reduced (P < 0.01,P < 0.05), TG, HDL-C had no change (P > 0.05) in NC group of simvastatin treatment. Conclusion Simvastatin decreased breakdown of matrix collagen, and inflammatory reaction in the patients of both NC and HC levels of ACS which may have effect on plaque stabilization.

(PDF emailed within 1 workday: $29.90)

Accession: 012003387

Download citation: RISBibTeXText


Related references

Effect of Xinmaitong capsule on serum matrix metalloproteinases-9, high sensitive C-reactive protein levels in patients with acute coronary syndrome. Zhongguo Zhong Yao Za Zhi 32(9): 850-852, 2007

Serum levels of matrix metalloproteinases-2 and tissue inhibitor of metalloproteinases-2 in chronic hepatitis. Gastroenterology 110(4 SUPPL ): A1192, 1996

Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms. Bulletin of Experimental Biology and Medicine 149(5): 628-631, 2011

Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hialuronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints. Przeglad Epidemiologiczny: Supplement 1, 20-29, 2008

Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hyaluronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints. Przeglad Epidemiologiczny 62 Suppl 1: 20-29, 2012

Clinical evaluation of serum levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases as predictors of progressive fibrosis in postoperative biliary atresia patients. Journal of Pediatric Surgery 37(7): 1030-1033, 2002

Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. Journal of Rheumatology 31(2): 238-242, 2004

AB0447Regulation of Serum Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases-1 following Rituximab Therapy in Patients with Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Blockers. Annals of the Rheumatic Diseases 73(Suppl 2): 956.1-956, 2014

Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers. Rheumatology International 35(4): 749-755, 2016

Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor. Plos One 7(11): E49042, 2013

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 45(4): 414-420, 2005

Levels of tissue inhibitor of metalloproteinases-1 and matrix metalloproteinases-1 and -8 in gingival crevicular fluid following treatment with enamel matrix derivative (EMDOGAIN). Journal of Periodontal Research 36(5): 309-316, 2001

Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. Arthritis and Rheumatism 52(9): 2751-2760, 2005

Limited value of preoperative serum analyses of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in colorectal cancer. Anticancer Research 20(2B): 1085-1092, March-April, 2000

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in serum from patients with colorectal cancer. Tumor Biology 19(SUPPL 2): 34, 1998